Patents by Inventor Josephine M. Cardarelli

Josephine M. Cardarelli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100021479
    Abstract: The invention pertains to anti-CD30 antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity, including the ability to lyse CD30-expressing cell lines that are not lysed by the fucosylated form of the antibodies. The invention also provides host cells that express the anti-CD30 antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of CD30+ cells, such as tumor cells, are also provided.
    Type: Application
    Filed: February 17, 2006
    Publication date: January 28, 2010
    Applicant: MEDAREX INC.
    Inventors: Josephine M. Cardarelli, Amelia Nancy Black
  • Publication number: 20090324605
    Abstract: The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the biological activity of IFN alpha using the antibodies of the invention, as well as methods of treating disease or disorders mediated by IFN alpha, such as autoimmune diseases, transplant rejection and graft versus host disease, by administering the antibodies of the invention.
    Type: Application
    Filed: August 31, 2009
    Publication date: December 31, 2009
    Applicant: Medarex, Inc.
    Inventors: Alison Witte, Denise Williams, Josephine M. Cardarelli, David King, David Passmore
  • Publication number: 20090297438
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PSMA with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating cancer.
    Type: Application
    Filed: February 17, 2006
    Publication date: December 3, 2009
    Inventors: Haichun Huang, David John king, Chin Pan, Josephine M. Cardarelli
  • Patent number: 7619070
    Abstract: Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.
    Type: Grant
    Filed: April 23, 2004
    Date of Patent: November 17, 2009
    Assignee: Medarex, Inc.
    Inventors: Josephine M. Cardarelli, Tseng-Hui Timothy Chen, David J. King, Christopher R. Bebbington, Sarah Lee Pogue, Francis J. Carr, Stephen Williams
  • Publication number: 20090217401
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
    Type: Application
    Filed: May 2, 2006
    Publication date: August 27, 2009
    Applicant: MEDAREX, INC
    Inventors: Alan J. Korman, Mohan Srinivasan, Changyu Wang, Mark J. Selby, Bing Chen, Josephine M. Cardarelli
  • Publication number: 20090162372
    Abstract: The present invention provides anti-ED-B antibodies, antibody fragments, and antibody mimetics and such antibodies conjugated to a partner molecule, wherein the antibody or the antibody-partner molecule conjugate provides a therapeutic effect regardless of whether the ED-B-antibody or ED-B-conjugate complex is internalized within a targeted cell.
    Type: Application
    Filed: November 14, 2008
    Publication date: June 25, 2009
    Applicant: Medarex, Inc.
    Inventors: David J. KING, Jonathan A. Terrett, Sanjeev Gangwar, Josephine M. Cardarelli, Chetana Rao-Naik, Chin Pan
  • Publication number: 20090142349
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to CD19 with high affinity. Nucleic acid molecules encoding such CD19 antibodies, expression vectors, host cells and methods for expressing the CD19 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the CD19 antibodies are also provided. Methods for detecting CD19, as well as methods for treating various B cell malignancies, including non-Hodgkin's lymphoma, are disclosed.
    Type: Application
    Filed: June 20, 2006
    Publication date: June 4, 2009
    Applicant: MEDAREX, INC.
    Inventors: Chetana Rao-Naik, David John King, Jie Liu, Haichun Huang, David B. Passmore, Alasdair Fraser Bell, Josephine M. Cardarelli, Chin Pan, To Uyen Thi Do, Sharline Chen, Dawn M. Tanamachi
  • Publication number: 20090060908
    Abstract: The invention pertains to anti-PSMA antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity as compared to the fucosylated form of the antibodies. The invention also provides host cells that express the anti-PSMA antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of PSMA+ cells, such as tumor cells, are also provided.
    Type: Application
    Filed: February 17, 2006
    Publication date: March 5, 2009
    Applicant: Medarex, Inc.
    Inventors: Josephine M. Cardarelli, David B. Passmore, Jenny Albanese, Lei Zhu
  • Publication number: 20090028872
    Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to CD70 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for treating cancer, autoimmune disease, inflammation and viral infections.
    Type: Application
    Filed: September 26, 2006
    Publication date: January 29, 2009
    Inventors: Jonathan Alexander Terret, Li-Sheng Lu, David John King, Josephine M. Cardarelli, Chin Pan, Haichun Huang, Marco A. Coccia
  • Publication number: 20080279868
    Abstract: The present disclosure provides antibody-drug conjugates that are potent cytotoxins, wherein the drug is linked to the antibody through a linker. The disclosure is also directed to compositions containing the antibody-drug conjugates, and to methods of treatment using them.
    Type: Application
    Filed: September 26, 2006
    Publication date: November 13, 2008
    Applicant: Medarex, Inc.
    Inventors: Sharon Elaine Boyd, Liang Chen, Sanjeev Gangwar, Vincent Guerlavais, Kilian Horgan, Bilal Sufi, Haichun Huang, David John King, Chin Pan, Josephine M. Cardarelli
  • Publication number: 20080253962
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to IRTA-4 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting IRTA-4, as well as methods for treating various B cell malignancies, including non-Hodgkin's lymphoma.
    Type: Application
    Filed: September 19, 2005
    Publication date: October 16, 2008
    Applicant: Medarex, Inc
    Inventors: Mohan Srinivasan, Josephine M. Cardarelli, Haichun Huang
  • Publication number: 20080247944
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to IRTA-2 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting IRTA-2, as well as methods for treating various B cell malignancies, including non-Hodgkin's lymphoma.
    Type: Application
    Filed: January 12, 2006
    Publication date: October 9, 2008
    Inventors: Robert Graziano, David J. King, Mohan Srinivasan, Josephine M. Cardarelli, Haichun Huang
  • Publication number: 20080187547
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to IRTA-5 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting IRTA-5, as well as methods for treating various B cell malignancies, including non-Hodgkin's lymphoma.
    Type: Application
    Filed: December 18, 2007
    Publication date: August 7, 2008
    Inventors: Robert Graziano, Josephine M. Cardarelli, Thomas D. Kempe, Beth Cutter, Mohan Srinivasan